Organisation paid for research Program year 2024 Source: CMS Open Payments

Vital Pharma Reseach

Neither a doctor nor a teaching hospital

Research payments

$164,305

102 payments

Through program year 2024, Vital Pharma Reseach is reported as receiving $164,305 in research payments, across 102 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2024	Research	$2,115	1
2023	Research	$61,639	24
2022	Research	$100,551	77

Breakdown

Who paid Research payments · program years 2022–2024

Myovant Sciences GmbH $100,551 77 payments
Sumitomo Pharma America, Inc. $63,754 25 payments

Studies the money was for Research payments · program years 2022–2024

A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy $74,194 35 payments
Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis $51,177 55 payments
Serene $36,819 11 payments
A Phase 3 Singlearm Openlabel Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids Or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy $2,115 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.